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Abstract
Muscular dystrophies are a large heterogeneous group of inherited diseases that cause progressive muscle
weakness and permanent muscle damage. Very few muscular dystrophies show sufficient specific clinical features
to allow a definite diagnosis. Because of the currently limited capacity to screen for numerous genes
simultaneously, muscle biopsy is a time and cost-effective test for many of these disorders. Protein analysis
interpreted in correlation with the clinical phenotype is a useful way of directing genetic testing in many types of
muscular dystrophies. Immunohistochemistry and western blot are complementary techniques used to gather
quantitative and qualitative information on the expression of proteins involved in this group of diseases.
Immunoanalysis has a major diagnostic application mostly in recessive conditions where the absence of labelling
for a particular protein is likely to indicate a defect in that gene. However, abnormalities in protein expression can
vary from absence to very subtle reduction. It is good practice to test muscle biopsies with antibodies for several
proteins simultaneously and to interpret the results in context. Indeed, there is a degree of direct or functional
association between many of these proteins that is reflected by the presence of specific secondary abnormalities
that are of value, especially when the diagnosis is not straightforward.
Introduction
The term muscular dystrophies (MDs) refers to a large
group of genetically inherited disorders characterised by
weakness and wasting of skeletal muscle. The subclassi-
fication is based on mode of inheritance, age of onset
and distribution of muscles affected. Progress made in
the past 25 years has enabled the discovery of new cau-
sative genetic defects with many novel proteins involved
in MD (an updated list of MDs and responsible genes
can be found at http://www.musclegenetable.org).
Despite remarkable advances, this work is not yet com-
plete, and although a large number of genes have been
identified, a considerable number of patients still remain
undiagnosed. Although a cure for most MDs is not yet
available, an accurate diagnosis is key for natural history
studies and to establish priorities for medical manage-
ment, therapy and genetic counselling. Physical exami-
nation to determine the distribution of symptoms,
together with medical and family history is central, but
often the underlying genetic defect cannot be conclu-
sively recognised on the basis of clinical information
only. Indeed, differential diagnosis has to take into
account the overlap of clinical features in different
forms of MD and the heterogeneity in clinical presenta-
tion for many of the genes involved. Searching for gene
mutations is the diagnostic gold standard but despite
the rapidly evolving sequencing technologies, the analy-
sis of multiple genes is still costly and time consuming
and classification of gene mutations as pathogenic
remains considerably challenging.
A wide range of laboratory tests aid in the diagnostic
process. Serum level of creatine kinase (CK) is a sensi-
tive parameter of muscle damage. The degree of CK ele-
vation is variable in different MDs and it can give an
approximate indication of the type of disorder [1]. Elec-
tromyography enables differentiation between myopathic
and neurogenic processes. Muscle magnetic resonance
imaging, used to determine patterns of muscle involve-
ment, represents a promising advance in facilitating dif-
ferential diagnosis [2-4]. In this context, the analysis of
t h em u s c l eb i o p s yp l a y sak e yr o l ei nt h ea s s e s s m e n to f
patients with MDs and provides useful diagnostic infor-
mation to direct genetic analysis.
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Although none of the types of MD can be distinguished
on basic muscle histology, histopathology screening
enables the identification of a number of features of sig-
nificance when reviewed in context with clinical infor-
mation. Many of the morphological abnormalities of
muscle can be recognised in haematoxylin and eosin
stained sections. Features such as fibre necrosis and
regeneration, fibrosis and fatty infiltration, inflammation
and vacuolated fibres seen in MDs are not specific to
any particular type [5].
Diagnostic capabilities greatly improve when histolo-
gical and histochemical tests are complemented with
protein analysis. The development of antibodies (ABs)
for many of the proteins affected in MDs has enabled
the design of effective immunodiagnostic protocols to
direct genetic screening. Identification of protein
defects relies on immunohistochemical preparations
and western blot analysis. Table 1 summarises the
commercial ABs available for the analysis of MDs with
both techniques. Tissue preparation and handling is
key to the outcome of the immunoanalysis. To avoid
ice crystal artefacts, skeletal muscle prepared for
immunohistochemistry should be frozen in isopentane
cooled in liquid nitrogen and stored at -80°C or in
liquid nitrogen. Provided that protein degradation is
excluded, absence of labelling for one protein generally
indicates a primary defect in the gene encoding for
that protein, and reduced labelling may still be useful
to suggest where to start the genetic analysis. In some
cases (for example, dystrophinopathy) one protein may
be abnormally expressed and others secondarily
reduced. For this reason it is generally recommended
to test each sample with several ABs and to interpret
the results by examining all proteins concurrently.
Clinical data are essential not only to interpret the
findings but also to select the appropriate ABs for
screening, which can vary according to the diagnosis
suggested. However, testing with all of the available
ABs is recommended as it may lead to the identifica-
tion of primary protein defects in patients with unu-
sual phenotypes [6,7]. Since biochemical analysis
requires a significant portion of a muscle biopsy, mul-
tiplex western blot techniques have become popular in
diagnostic laboratories to detect several proteins simul-
taneously [7]. Proteins separated by gel electrophoresis
and labelled by immunoblot can be evaluated by size
(molecular mass) and intensity (abundance) compared
to a control. A loading control such as myosin heavy chain
should be used to indicate how much ‘muscle’ protein is
loaded in each sample and to establish an adequate base-
line for protein quantification, since dystrophic muscle
samples may be fibrotic or contain fat. Importantly, biopsy
of end stage muscle is unlikely to provide diagnostic
information due to loss of myofibres and predominance of
fibrovascular and adipose tissue. However a symptomatic
muscle should be selected to appreciate distinctive patho-
logic features. Ultrasound or MRI techniques may aid the
selection of the biopsy site [4,8].
Table 1 Commercial antibodies for the diagnosis of
muscular dystrophies
Antigen Host/Isotype Clone IHC WB
Spectrin Mouse IgG2b RBC2/3D5 Y N
Dystrophin (N term) Mouse IgG2a Dy10/12B2 Y Y
Dystrophin (rod domain) Mouse IgG2a Dy4/6D3Y Y Y
Dystrophin (C-term) Mouse IgG1 Dy8/6C5 Y Y
Dystrophin (C-term) Mouse IgG1 MANDRA1 Y Y
Utrophin Mouse IgG1 DRP3/20C5 Y N
nNOS Mouse IgG1 RN5 Y N
Myotilin Mouse IgG1 RS034 Y N
Lamin A/C Mouse IgG2b 636 Y* N
Caveolin-3 Mouse IgG1 26/Caveolin 3 Y Y
Calpain-3 Mouse IgG2b Calp3d/2C4 N Y
Calpain-3 Mouse IgG2a Calp3d/12A2 N Y
Dysferlin Mouse IgG1 Ham1/7B6 Y Y
Dysferlin Mouse IgG2b Ham3/17B2 Y N
a-Sarcoglycan Mouse IgG1 Ad1/20A6 Y Y
b-Sarcoglycan Mouse IgG1 b-sarc/5B1 Y N
g-Sarcoglycan Mouse IgG2b 35DAG/21B5 Y Y
δ-Sarcoglycan Mouse IgG2a d-sarc3/12C1 Y N
Telethonin Mouse IgG1 G-11 N N
a-Dystroglycan Mouse IgM IIH6 Y Y
a-Dystroglycan Mouse IgG1 VIA4-1 Y Y
b-Dystroglycan Mouse IgG2a 43DAG1/8D5 Y Y
Laminin a2 80kDa Mouse IgG1 5H2 Y Y
Laminin a2 300kDa Mouse IgG1 Mer3/22B2 Y N
Laminin a2 300kDa Rat IgG1 4H8 Y N
Laminin a5 Mouse IgG2a 4C7 Y N
Laminin b1 Mouse IgG1 4E10 Y* N
Laminin g1 Mouse IgG1 2E8 Y N
Laminin g1 Mouse IgG2a A5 Y N
Collagen VI Mouse IgG1 3C4 Y N
Collagen VI Rat IgG1 VI-26 Y N
Perlecan Mouse IgG2a A7L6 Y N
Emerin Mouse IgG1 4G5 Y N
Desmin Mouse IgG1 D33 Y N
aB-Crystallin Rabbit Polyclonal G2JF Y N
VCP Mouse IgG1 18/VCP Y N
PTRF-cavin Mouse IgG1 4/PTRF N Y
MHC class I Mouse IgG2a W6-32 Y N
Neonatal Myosin Mouse IgG1 WB-MHCn Y N
The list includes antibodies for the detection of primary or secondary defects
and for the assessment of quality and preservation of samples.
*Immunoanalysis possible but not informative for diagnostic assessment.
IHC = immunohistochemistry; MHC = major histocompatibility complex; N = labelling
not carried out routinely or antibody nott e s t e d / n o ts u i t a b l ef o rt e s t ;n N O S=
neuronal nitric oxide synthase; PTRF = polymerase I and transcript release factor; VCP
= valosin-containing protein; WB = western blot; Y = labelling carried out routinely.
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preservation of samples as well as to discriminate patho-
logical from natural changes (Table 2). In immunohisto-
chemistry, the AB to b-spectrin serves as a marker of
sarcolemmal integrity and it is used to evaluate the
expression of plasma membrane proteins. In fact, necro-
tic fibres or fibres within degraded biopsies generally
lack sarcolemmal labelling and could give false negative
results. Similarly, ABs for laminin g1 and perlecan can
be used to check the integrity of the basal lamina if a
reduction in laminin a2 or collagen VI is detected. By
contrast, laminin b1 chain is not suitable for this pur-
pose as it is often secondarily reduced in both recessive
and dominant conditions [9]. Importantly, the expres-
sion of some proteins is developmentally regulated. For
instance, b-spectrin and neuronal nitric oxide synthase
(nNOS) are weakly expressed in regenerating fibres,
which instead label for markers such as utrophin, des-
min and major histocompatibility complex (MHC) class
I [10] (Figure 1 and data not shown). Laminin a5i sa l s o
present in regenerating fibres but its expression may
also be increased in dystrophinopathies and inflamma-
tory myopathies (Figure 1). To facilitate the interpreta-
tion of these findings serial sections should also be
labelled for neonatal myosin heavy chain (Neo-MHC),
as a marker of regenerating fibres, but caution is needed
since Neo-MHC is also found in fibres with arrested
development (Figure 1) and atrophic fibres and reap-
pears after denervation [5,11]. Other isoforms of MHC,
such as embryonic MHC, are expressed more transiently
in earlier stages and can be detected mainly in the smal-
ler regenerating fibres [10].
Investigation of specific disorders
Protein analysis is effective in guiding genetic analysis
in many, but not all, types of MDs (Table 3). Its major
diagnostic application is in recessive conditions where
the protein defect can vary from absence to partial
reduction. In most dominant diseases the results may
be inconclusive, as both normal and abnormal alleles
produce protein. Also, genetic analysis is very reliable
in conditions such as myotonic dystrophy and faciosca-
pulohumeral muscular dystrophy (FHSD) and a diag-
nosis can be achieved without the need of a muscle
biopsy. Details of clinical features of MDs and other
diagnostic techniques are not discussed in the present
review. Here we focus on the pattern of protein
expression and specific secondary changes in those
types of MDs where the analysis of muscle biopsy with
commercially available ABs plays a major role in facili-
tating the diagnosis.
Genes affected in MDs encode for diverse proteins
with various distribution and function within the muscle
cell. Direct or functional association between many of
these proteins is reflected b yt h ep r e s e n c eo fs p e c i f i c
secondary abnormalities that are of diagnostic value. In
particular, the expression of proteins of the dystrophin
glycoprotein complex (DGC) appear to be strictly inter-
related, therefore forms of MDs that affect this group of
proteins are discussed together in this review.
Table 2 Protein controls for immunohistochemistry
Control purpose Protein Normal expression Secondary changes Notes
Preservation of
plasma membrane
Spectrin Sarcolemma Reduction in immature/regenerating fibres.
Absent or patchy in necrotic fibres.
Absent of patchy in biopsies with artefacts.
May be reduced in fibres with Neo-MHC,
utrophin, laminin a5, MHC class I.
Absence of other sarcolemmal proteins.
Regenerating
fibres
Neo-MHC Fibres unlabelled Labelling of regenerating fibres.
Labelling of atrophic fibres.
Coexpressed with laminin a5, MHC class
I, utrophin
Regenerating
fibres
Utrophin Vessels, nerves and
neuromuscular junction
Labelling of regenerating fibres.
Labelling of mature fibres in DMD/BMD.
Coexpressed with Neo-MHC, laminin a5,
MHC class I
Regenerating
fibres, denervation
nNOS Sarcolemma Reduction in regenerating and denervated
fibres.
Absent in DMD, some BMD and
sarcoglycanopathies.
Reduced in fibres expressing utrophin,
Neo-MHC, laminin a5, MHC class I
Regenerating
fibres
Laminin
a5
Blood vessels Labelling of regenerating fibres. Labelling of
mature fibres in MDC1A.
Coexpressed with utrophin, Neo-MHC,
laminin a5, MHC class I
Inflammation,
regenerating fibres
MHC class
I
Blood vessels Labelling of regenerating fibres.
Sarcolemmal labelling in diseases with
inflammatory component.
Coexpressed with utrophin, Neo-MHC,
laminin a5
Basement
membrane,
integrity
Laminin b1 Sarcolemma and blood
vessels
Sarcolemmal labelling reduced or patchy in
many dominant and recessive conditions
Basement
membrane,
integrity
Laminin
g1,
Perlecan
Sarcolemma and blood
vessels
Patchy in biopsies with artefacts
DMD/BMD Duchenne/Becker muscular dystrophy; MDC1A = congenital muscular dystrophy type 1A; MHC = major histocompatibility complex; Neo-MHC =
neonatal myosin heavy chain; nNOS = neuronal nitric oxide synthase.
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Page 3 of 15Figure 1 Control tests for necrosis and regeneration. Expression of various markers of sarcolemmal integrity (b-spectrin) and regeneration
(neonatal myosin heavy chain (Neo-MHC), utrophin and laminin a5) in serial sections of control, Duchenne muscular dystrophy (DMD) and limb
girdle muscular dystrophy (LGMD)2B muscle. Arrows indicate abnormal immature fibres positive for Neo-MHC; stars highlight regenerating fibres
at different stages. The pattern of expression of the regeneration markers is less defined in DMD muscle due to the overall upregulation of
utrophin and laminin a5 and secondary loss of neuronal nitric oxide synthase (nNOS).
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Many of the MD types involve members of the DGC, a
group of proteins that links the intracellular cytoskeleton
and the extracellular matrix [12-15] (Figure 2). Dystrogly-
can (a-DG and b-DG) is the transmembrane axis that
connects proteins of the extracellular matrix (for exam-
ple, laminin-2) and dystrophin [12]. The dystrophin
molecule has an N-terminal actin-binding domain fol-
lowed by 24 repeat units (rod domain), a C-terminus that
contains a cysteine-rich domain that binds to b-DG
[16,17] followed by a region that associates with dystro-
brevin, syntrophins and, indirectly, with nNOS [18,19]. In
skeletal muscle the DGC also contains four sarcoglycans
(a, b, g and δ-SG) and sarcospan [20], all of which are
Table 3 Primary and secondary protein abnormalities in muscular dystrophies
Disease Gene(s) Primary protein defect Secondary changes
DMD DMD Dystrophin absent or very reduced with all antibodies Utrophin overall upregulated
Sarcoglycans reduced/absent
Dystroglycan reduced/absent nNOS
absent
BMD DMD Dystrophin reduced in size or amount or absent with at
least one antibody
Utrophin overall upregulated
Sarcoglycans reduced/absent
Dystroglycan reduced/absent
nNOS may be absent
DMD/BMD carriers DMD Dystrophin patchy, mosaic pattern with at least one
antibody
In fibres without dystrophin
Utrophin upregulated
Sarcoglycans reduced/absent
Dystroglycan reduced/absent
nNOS may be absent
EDMD1 EMD Emerin absent
LGMD1A MFM MYOT Myotilin cytoplasmic aggregates Desmin, aB-crystallin, VCP cytoplasmic
aggregates
LGMD1B EDMD2
EDMD3
LMNA Lamin A/C normally expressed
LGMD1C rippling muscle
disease hyperCKemia
CAV3 Caveolin-3 absent/reduced Dysferlin reduced at the sarcolemma
LGMD2A CAPN3 Calpain 3 bands may be variably reduced on
immunoblot, Iabelling may be absent or reduced on
sections
Dysferlin reduced at the sarcolemma
LGMD2B Miyoshi
myopathy
DYSF Dysferlin absent or very reduced Caveolin-3 reduced at the
sarcolemma, calpain 3 bands may be
reduced
LGMD2C-F SGCG SGCA
SGCB
SGCD
Sarcoglycans variably reduced/absent b-Dystroglycan may be reduced
Dystrophin may be reduced
nNOS may be absent
LGMD2G TCAP Telethonin absent
LGMD2I, K, M-O, DG-
pathies
FKRP POMT1 FKTN
POMT2 POMGnT1
LARGE
Not applicable Glycosylated a-dystroglycan very
reduced/patchy
b-dystroglycan may be reduced
Laminin a2 may be reduced
MDC1A LAMA2 Laminin a2 completely or partially absent Laminin a5 overall upregulated
a-dystroglycan may be reduced
UCMD and Bethlem
myopathy
COL6A1 COL6A2
COL6A3
Collagen VI very reduced in UCMD, usually normally
expressed in BMD
MD with lipodystrophy PTRF PTRF-cavin absent/very reduced Caveolin-3 reduced at the sarcolemma
MFM DES Desmin cytoplasmic aggregates Myotilin, aB-crystallin, VCP cytoplasmic
aggregates
MFM CRYAB aB-Crystallin cytoplasmic aggregates Myotilin, desmin, VCP cytoplasmic
aggregates
IBMPFD VCP VCP cytoplasmic aggregates Myotilin, desmin, aB-crystallin
cytoplasmic aggregates
BMD = Becker muscular dystrophy; CK = creatine kinase; DG-pathies = dystroglycanopathies; DMD = Duchenne muscular dystrophy; EDMD = Emery-Dreifuss
muscular dystrophy; IBMPFD = inclusion body myopathy with Paget’s disease and frontotemporal dementia; LGMD = limb girdle muscular dystrophy; MD =
muscular dystrophy; MDC = congenital muscular dystrophy; MFM = myofibrillar myopathy; nNOS = neuronal nitric oxide synthase; PTRF = polymerase I and
transcript release factor; UCMD = Ulrich congenital muscular dystrophy; VCP = valosin-containing protein.
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fukutin-related protein (FKRP) may be an integral com-
ponent of the DGC [21]. Faults in components or ligands
of the DGC complex (as observed in dystrophinopathy,
sarcoglycanopathies, dystroglycanopathies and laminin
a2 deficiency) cause disruption of the structural link that
protects the muscle fibres from damage caused by con-
traction, and lead to muscular dystrophy [22].
Dystrophinopathies
Dystrophin is the product of the DMD gene, located on
the X chromosome. This is a very large gene with a
high rate of new mutations with recessive inheritance
pattern. Duchenne and Becker muscular dystrophies
(DMD and BMD, respectively) are common in male
patients, but symptomatic female carriers have also been
described [23]. Due to the high incidence of dystrophi-
nopathies compared with other forms of MD, ruling in
or out DMD/BMD should always be the first diagnostic
step. Deletions of the DMD gene account for 65% of
cases and can be detected directly by molecular analysis.
This test has eliminated the need for muscle biopsy in
many cases of ‘classic’ dystrophinopathies but immunoa-
nalysis still remains an important diagnostic tool [24,25].
Abnormal expression of dystrophin is the hallmark for
the diagnosis of DMD/BMD. In general, severe muta-
tions with disruption of the reading frame result in
absence of dystrophin and cause DMD, while milder
mutations with expression of dystrophin of reduced
amount or variable mass cause BMD [26]. Due to the
large size of dystrophin it is important to use ABs direc-
ted against several sites of the protein, to avoid false-
negative results due to deletion of specific epitopes. A
panel of ABs directed against N-terminal, C-terminal
and rod domain is routinely used in diagnostic labora-
tories. Western blotting should always be employed in
parallel since it offers clues on the type of mutation pre-
sent. In addition, quantification of the residual amount
of dystrophin, if any, is useful for the prognosis of dis-
ease severity [27].
Total absence of dystrophin (Figure 1) or limited
labelling on a very small proportion of revertant fibres
[28] is specific for the diagnosis of DMD. In contrast,
v a r i a t i o ni nd y s t r o p h i ne x p r e s s i o nm a yb em o r es u b t l e
in patients with BMD. The use of an AB panel for dys-
trophin is of particular diagnostic value in these cases.
Although commercial ABs for dystrophin can detect
abnormal protein with the most common in-frame dele-
tions, absence of labelling for an AB indicates deletion
of that particular epitope. More frequently, in BMD the
intensity of the labelling for one or more AB is variable
(Figure 3), but occasionally samples show levels of dys-
trophin similar to control on sections. Blotting of mus-
cle is especially useful in these cases, however if the
a b n o r m a l i t yi sv e r ys u b t l e ,t h ed i a g n o s i sm u s tr e l yo n
the assessment of secondary protein changes. Dystro-
phin expression is often abnormal in carriers of DMD,
and its analysis is important in order to exclude differ-
ential diagnoses of autosomal MD. Due to a skewed pat-
tern of X-inactivation in muscle, in transverse sections,
both positive and negative fibres can be observed in
variable proportion, which correlates with the severity of
the phenotype [29,30]. Usually in these cases the immu-
noblot does not show abnormalities since the mutated
dystrophin may be masked by the expression of the nor-
mal protein [31].
Secondary protein changes
There is value in including antibodies to other proteins
as secondary markers in routine immunohistochemical
studies for DMD and, especially, BMD. Utrophin, the
dystrophin homolog encoded on chromosome 6, is
expressed in normal adult fibres only at the neuromus-
cular junction, but in DMD/BMD biopsies it is strongly
upregulated at the sarcolemma [32]. As utrophin is also
expressed in regenerating fibres [33], appropriate mar-
kers should be used to distinguish the abnormal from
the normal expression (Figure 1). Utrophin is upregu-
lated in most, but not all, cases of BMD [34], therefore
it is important to examine thee x p r e s s i o no fo t h e rp r o -
t e i n sw h e nt h ed i a g n o s i si sn o ts t r a i g h t f o r w a r d( F i g u r e
3). Abnormal expression of dystrophin in DMD, BMD,
and manifesting carriers is accompanied by a secondary
reduction of other DGC proteins. Reduced labelling for
sarcoglycans and a-DG and b-DG is common in dystro-
phinopathies [13-15,35]. Sarcolemmal nNOS is missing
Figure 2 The dystrophin glycoprotein complex (DGC).
Schematic representation of the core DGC and associated proteins.
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mid-rod domain [36], but results have to be interpreted
carefully since nNOS expression is very reduced in
regenerating and denervated fibres [37].
Limb girdle muscular dystrophy (LGMD)2C-F
(sarcoglycanopathies)
Primary defects responsible for MD have been found in
genes encoding for a, b, g and δ-SG. These cause reces-
sive LGMDs, now often referred to as the sarcoglycano-
pathies. The SGs act as a complex, such that a defect in
any one leads to absence or reduction in expression of
the other three SGs (Figure 3) [38]. However this is not
a rigorous finding and labelling for all four proteins
should be carried out to avoid misdiagnosing cases with
s e l e c t i v el o s so fo n eS G[ 3 9 ] .T h er e s u l t sf r o mA B st o
all four SGs are reliable in directing molecular analysis
when the immunolabelling for one SG is absent or
reduced and the expression of the others is retained
[38,40,41]. However in most cases expression of all SGs
can be variable and does not allow an accurate predic-
tion of the genotype [42].
Figure 3 Primary and secondary protein abnormalities in dystrophin glycoprotein complex (DGC)-related disorders. A full description is
given in the text. BMD = Becker muscular dystrophy; a-DG = a-dystroglycan; b-DG = b-dystroglycan; Dys-C = dystrophin C-terminal; Dys-N =
dystrophin N-terminal; lam-a2 = laminin a2; LGMD2D = sarcoglycanopathy with primary defect in the SGCA gene; LGMD2I =
dystroglycanopathy with primary defect in the FKRP gene; a-SG = a-sarcoglycan.
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The main clue to differentiate patients with sarcoglyca-
nopathy from BMD or manifesting carriers is a pattern
of reduced labelling for SGs in the presence of normal
dystrophin (Figure 3). However, reports of sarcoglycano-
pathy biopsies with abnormal labelling of dystrophin
and b-dystroglycan exist [41-43]. The abnormalities in
these cases are mild than the defect in SGs expression
[44]. In a male, if expression of all SGs and dystrophin
is reduced it may be difficult to determine the primary
defect without the aid of secondary protein abnormal-
ities. Utrophin is usually not upregulated in LGMD2D-F
patients. However, some cases of BMD may not show
sarcolemmal utrophin (Figure 3), while occasional sarco-
glycanopathies may show utro p h i ne x p r e s s i o n[ 3 5 , 4 5 ] .
Loss of nNOS at the sarcolemma of patients with sarco-
glycanopathies has been described [46,47] but the inter-
pretation for diagnostic purposes is subject to the same
limitations as for dystrophinopathies.
Dystroglycanopathies
The gene DAG1 encodes the propeptide that is proteolyti-
cally cleaved into two non-covalently associated proteins,
a-DG and b-DG [48,49]. Primary dystroglycanopathy, due
to a defect in DAG1, is very rare and has been described
in only one patient to date [50]. Secondary dystroglycano-
pathies are more frequent and are caused by recessive
mutations in at least six known or putative glycosyltrans-
ferases: FKRP, fukutin (FCMD), protein O-mannosyl
transferase 1 (POMT1), protein O-mannosyl transferase 2
(POMT2), protein O-mannosyl b-1,2-N-acetylglucosami-
nyltransferase (POMGnT1), and LARGE [51,52]. Glycosy-
lation is the crucial modification that modulates the
function of a-DG as a receptor for extracellular binding
partners [12]. Modifications in these genes result in abnor-
mal glycosylation of a-DG and lead to neuromuscular dis-
orders that range from severe congenital onset with
associated brain malformations (Walker-Warburg syn-
drome, muscle-eye-brain disease, Fukuyama muscular dys-
trophy), to milder forms of congenital muscular dystrophy
(CMD) such as MDC1C and 1D, and to LGMD pheno-
types (LGMD2I, 2K, 2M, 2N, and 2O) [53-55]. Irrespective
of the gene, all the mutations seem to act in a common
pathway and the disease severity is possibly related to the
impact of a particular mutation on DG function.
Secondary protein changes
ABs for most proteins involved are not currently in use
for diagnosis. However abnormal labelling for a-DG is
common to all the dystroglycanopathies and it is an
indicator that the mutation may reside in one of the six
genes or in unknown genes in the same pathway. Glyco-
sylation defects are revealed by loss or reduction of
immunoreactivity to two ABs, VIA41 and IIH6, which
recognise carbohydrate moieties of a-DG (Figure 3)
[56]. The extent of a-DG reduction can vary from
severe to very subtle and can also be verified by immu-
noblot. While there is usually a good correlation
between reduced a-DG staining and phenotype in
patients with mutations in POMT1, POMT2 and
POMGnT1, this is not always true in patients with
defects in FKRP and FCMD [57]. Notably, labelling for
an AB directed against a core peptide of a-DG
(GT20ADG) is usually well preserved on muscle fibres
of dystroglycanopathy patients [56]. Consistently, this
AB detects hypoglycosylated a-DG with reduced mole-
cular mass but at levels similar to control on immuno-
blot [56-58]. Variable reduction of laminin a2 labelling
can occur, generally more evident on blot [51,59,60].
Laminin a5 is often overexpressed, although the finding
is not consistent in all dystroglycanopathy patients
(author’s observation). b-DG may be mildly reduced on
immunohistochemistry, but labelling on blot appears
within the normal range [57]. Furthermore, one clinical
report suggests that FKRP patients may have reduced
expression of other DGC components [61].
Congenital muscular dystrophy 1A (MDC1A,
laminin a2)
Approximately 50% of patients with CMD show defi-
ciency of laminin a2 expression in muscle [60]. Laminin
a2, with the laminin chains b1a n dg1, is a component
of laminin-2, the major constituent of the basal lamina
of muscle fibres. Normal muscle shows uniform sarco-
lemmal immunolabelling; in cases of MDC1A laminin
a2 may be absent or variably reduced [62]. Patients with
a partial deficiency usually have a milder phenotype
than those with absent or very reduced protein [60].
Laminin a2 is a large protein that on immunoblot
appears as 80 and 300 kDa fragments. It is good practice
to assess sections of muscle biopsies with ABs to both
fragments, particularly to diagnose cases with a partial
reduction [5]. Indeed, cases with unremarkable labelling
with the 80 kDa AB may show a considerable reduction
with the other AB [63]. Laminin a2 is expressed in sev-
eral tissues that can be used for diagnosis. In skin lami-
nin a2 is localised to the epidermal/dermal junction and
to the nerve endings of the arrector pili smooth muscle
[64,65]. Prenatal testing can be carried out on chorionic
villi from placentas of 8-23 weeks, which express most
laminin chains [66]. The absence of laminin a2 is easily
observed in these tissues, but cases with partial defi-
ciency may be difficult to identify [64,66,67].
Secondary protein changes
Upregulation of laminin a5 is observed in cases of total
and partial laminin a2 deficiency [62]. This may be
especially helpful for the diagnosis of cases with partial
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normally present on immature and regenerating fibres.
Reduction of a-DG labelling may occur, which generates
confusion in cases of partial laminin a2 deficiency [68].
LGMD1A (myotilin) and myofibrillar myopathies
Myotilin is a sarcomeric protein that is expressed at the
Z line of skeletal muscle and is involved in the organisa-
tion and stabilisation of thin filaments and the sarco-
mere [69]. Mutations in the MYOT gene with LGMD1A
phenotype have been identified in only two unrelated
families [70,71], but the gene is also mutated in other
forms of muscle disease such as myofibrillar myopathy
(MFM), spheroid body myopathy, and late onset distal
myopathy [72-74]. Signs of myotilinopathy include gran-
ular or hyaline accumulations that stain dark blue or
red with Gomori trichrome (cytoplasmic bodies),
vacuoles frequently rimmed by basophilic or red mate-
rial with haematoxylin and eosin and Gomori trichrome,
respectively, and streaming Z lines [72]. These structural
abnormalities are also common features of the large
group of MFMs [75], caused by mutations not only in
MYOT but also in a number of other genes. MFM
genes identified so far encode for desmin, aB-crystallin,
Z band alternatively spliced PDZ-motif-containing pro-
tein (ZASP), filamin C, four-and-a-half LIM domain 1
(FHL1), BCL2-associated athanogene 3 (BAG3), and
plectin (for review see [76]). This class of dominantly
inherited diseases is difficult to differentiate based on
histology only and clinical features are often better indi-
cators of where the primary genetic defect may lie.
Some histological findings can facilitate the diagnosis,
for example spheroid bodies in Gomori trichrome stain
may indicate a myotilinopathy or sarcoplasmic reducing
bodies positive for menadione-NBT indicate FHL1opa-
thy [76,77]. Antibodies directed against desmin, aB-crys-
tallin and myotilin are good diagnostic tools to detect
p r o t e i na c c u m u l a t i o ni nM F M .H o w e v e rt h en u m b e ro f
affected fibres can be very variable, with some samples
showing a large abundance and others only displaying a
few abnormal fibres. Therefore protein tests may be
unspecific or normal in genetically confirmed MFMs
[ 7 6 ] .F u r t h e r m o r e ,i tm u s tb ek e p ti nm i n dt h a tm i n i -
cores, central cores, and target fibres also show
increased reactivity with these antibodies [76]. Accumu-
lations of other sarcolemmal proteins such as dystro-
phin, SGs and caveolin-3 may also be seen in MFM
[75]. Similar findings may be observed in biopsies from
patients with valosin-containing protein (VCP)-related
inclusion body myopathy associated with Paget’s disease
of bone and frontotemporal dementia which, therefore,
should not be excluded as a differential diagnosis [78].
In summary, histology and immunoanalysis in the con-
text of clinical data are useful to achieve a generic
diagnosis for MFM, but immunolabelling is rarely con-
clusive in identifying the affected gene.
LGMD1C (caveolin-3)
Mutations in the CAV3 gene cause LGMD1C [79,80].
The muscle biopsies show a severe reduction of caveo-
lin-3 at the sarcolemma. Caveolin-3 is localised at small
invaginations of the plasma membrane (caveolae) and
interacts with b-DG, but it is not an integral part of the
DGC [81]. Mutations in CAV3 have also been found in
hyperCKemia, distal myopathy, and rippling muscle dis-
ease, with many patients showing an overlap of the phe-
notypes. Although these disorders are mainly inherited
in an autosomal dominant fashion, occasional autosomal
recessive cases have been reported [82]. A mosaic pat-
tern of reduction of caveolin-3 at the sarcolemma is
detected in patients with immune-mediated rippling
muscle disease (Figure 4). In these patients caveolin-3
may not be significantly reduced on blots [83]. More
recently, secondary reduction of caveolin-3 at the sarco-
lemma has been described in patients with mutations in
the gene encoding for polymerase I and transcript
release factor (PTRF)-cavin, a caveolar-associated pro-
tein that plays a role in the formation of caveolae and
the stabilisation of caveolins [84,85]. Abnormal localisa-
tion of dysferlin is often seen in muscle from patients
with LGMD1C, indicating a structural or functional
interaction between these proteins [86]. In the absence
of caveolin-3, dysferlin accumulates in the cytoplasm
and displays an irregular sarcolemmal distribution
(Figure 4).
LGMD2A (calpain 3)
Calpain 3 (CAPN3), a muscle specific calcium-activated
neutral protease, is the defective protein in LGMD2A
[87]. Several cytoskeletal proteins are substrates for
CAPN3, but this protein also displays autolytic activity
and it is cleaved into a N-terminal fragment of 30 kDa
and C-terminal fragments of 60 to 45 kDa [88,89]. Two
ABs are mainly used for the detection of CAPN3 (Table
1). Until recently [90,91], it was thought that these only
work on immunoblot where they produce characteristic
patterns of bands: full length CAPN3 (94 kDa), plus the
additional degradation fragments (Figure 4 and data not
shown) [92]. Immunocytochemical studies of CAPN3
are limited but promising, showing intracellular labelling
with both ABs, which is absent in most LGMD2A
patients [90,91]. Dysferlin membrane labelling may be
secondarily reduced (Figure 4) [93].
Protein-based diagnosis for LGMD2A is not always
fully reliable. Expression of full-length protein and
degradation fragments has to be expertly evaluated to
establish whether a defect is genuine or secondary.
Indeed numerous factors influence the expression and
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have been described in several muscular dystrophies,
including LGMD2B and LGMD2J [94,95]. Moreover,
CAPN3 reduction is often observed in many dystrophic
biopsies, perhaps as a consequence of rapid degradation
and/or biopsy processing conditions [96]. In contrast,
normal CAPN3 expression may be seen in patients with
confirmed molecular diagnosis of LGMD2A [97]. There-
fore data on CAPN3 expression must be interpreted by
taking into account issues related to protein degradation
and abnormalities of other LGMD proteins. For patients
with a strong clinical suspicion for LGMD2A and nor-
mal CAPN3 expression the diagnosis relies on genetic
analysis, but there is also value in using functional in
vitro assays for the autolytic activity of CAPN3 [98].
Dysferlinopathies
Dysferlin is the product of the gene responsible for
LGMD2B, Miyoshi myopathy and distal anterior com-
partment myopathy [99-101]. This protein is widely dis-
tributed, although it predominates in striated muscle
where it localises to the sarcolemma and intracellular
Figure 4 Comparative expression of dysferlin, caveolin 3 and calpain 3. Expression of these proteins is primarily or secondarily affected in
patients with defects in the caveolin 3 (CAV3) gene (limb girdle muscular dystrophy (LGMD)1C), the dysferlin (DYSF) gene (LGMD2B) and the
calpain 3 (CAPN3) gene (LGMD2A). In a patient with mosaic expression of caveolin 3, fibres with loss of the protein also show reduced
sarcolemmal labelling for dysferlin (a). (b) Immunoblot is a more reliable technique for diagnosis of LGMD2A and 2B. b-DG = b-dystroglycan;
Dys-C = dystrophin C-terminal; a-SG = a-sarcoglycan.
Barresi Skeletal Muscle 2011, 1:24
http://www.skeletalmusclejournal.com/content/1/1/24
Page 10 of 15vesicles [102,103]. Primary defects in the DYSF gene
lead to severely reduced protein expression and subsar-
colemmal accumulation of vesicles [104]. CAPN3 and
caveolin-3 are often secondarily reduced in LGMD2B
(Figure 4) [105,106]. Secondary sarcolemmal reduction
of dysferlin is often seen in muscle biopsies of patients
with many other forms of muscular dystrophy but in all
these cases the band for dysferlin is normally detected
on immunoblot [86,104,107,108]. In contrast LGMD2B
and Miyoshi myopathy patients typically show complete
or partial absence of the dysferlin band on immunoblot
of skeletal muscle (Figure 4b) or blood monocytes
[109,110]. Some heterozygous carriers of LGMD2B also
display reduced dysferlin levels, as well as variable mus-
cle histopathological changes [111].
LGMD2G (telethonin)
LGMD2G is a rare condition described mainly in the
Brazilian population [112,113] and it is associated with
mutations in the gene for telethonin. Telethonin is a
sarcomeric protein expressed at the Z line in skeletal
and cardiac muscle, where it interacts with the C-term-
inal domain of titin [69,114]. Examination of muscle
biopsies from affected individuals shows absence of tele-
thonin and maintenance of the sarcomeric structure. All
the other proteins involved in muscular dystrophies are
normally expressed [114].
Emery-Dreifuss muscular dystrophy (EDMD)
Mutations in a number of genes are responsible for
EDMD. Interestingly, all genes involved encode for pro-
teins of the nuclear membrane. Both X-linked and auto-
somal forms have been described. EDMD1 is caused by
mutations in the EMD gene on the X chromosome that
encodes for emerin [115]. Mutations occur throughout
the gene and result in absence or mislocalisation of the
protein [116,117]. In female carriers a variable number
of emerin-positive and emerin-negative cells can be
detected [118]. Emerin is ubiquitously expressed, and
many tissues can be used as an alternative to muscle for
protein studies. In particular skin and cells from buccal
smears are frequently tested for diagnosis of X-linked
EDMD patients and female carriers [119-121].
EDMD2 is due to mutations in the LMNA gene that
encodes for lamins A and C, intermediate filaments of
the inner nuclear membrane in almost all cells. Muta-
tions in LMNA can cause several different phenotypes
including LGMD1B (for review see [122]). Inheritance is
autosomal dominant, but very rare autosomal recessive
cases (EDMD3) have been described [123]. Immunoana-
lysis in this type of disorder is not informative as no dif-
ference in the expression of lamin A/C in skeletal
muscle is detected due to the expression of the normal
allele.
New mutations have been found in the synaptic
nuclear envelope protein 1 (SYNE1) and in the synaptic
nuclear envelope protein 2 (SYNE2) genes in two
patients in two families, also called Nesprin-1 and
Nesprin-2, but too few cases have been identified to
know if immunolabelling has a role in diagnosis [124].
Mutations in the FHL1 gene have also been described in
association with X-linked EDMD [125].
Ullrich congenital muscular dystrophy (UCMD)
and Bethlem myopathy (collagen VI)
Collagen VI is a protein of the extracellular matrix,
which consists of three a chains, a1(VI) a2(VI) and a3
(VI), encoded by the COL6A1, COL6A2 and COL6A3
genes, respectively. Mutations in all three genes have
been reported in UCMD families [126-128] and in the
milder Bethlem myopathy [129,130]. Collagen VI is pre-
sent in most connective tissues and, in skeletal muscle,
localises in the basement membrane, endomysium and
perimysium. In the muscle of UCMD patients a spec-
trum of collagen VI anomalies can be found. The pro-
tein can be completely absent or the changes can be
difficult to detect, with only absence at the basal lamina
[127,131]. The subtle reduction makes it important to
evaluate the results by double labelling with another
antibody such as perlecan to verify the integrity of the
basal lamina [5]. It must be noted that normal or nearly
normal collagen VI immunolabelling does not exclude a
d i a g n o s i so fU C M D[ 1 3 2 ] .I nB e t h l e mm y o p a t h y ,c o l -
lagen VI immunolabelling of muscle is usually normal
or shows very subtle alterations [133].
Several reports have described an absence or a reduction
in the amount of secreted collagen VI in fibroblast cul-
tures from UCMD patients [128,134]. This technique has
am u c hh i g h e rp r e d i c t i v ev a l u eo fCOL6A mutations in
BM patients, since it allows detection of even very subtle
alterations in collagen VI expression and secretion [133].
Conclusions
Protein analysis is the most valuable and dependable
way of improving the efficiency of genetic testing in
many types of MDs. Diagnosis is achieved in a signifi-
cant proportion of patients when informative clinical
data and immunoanalysis results are available to guide
the molecular analysis [135]. The muscle biopsy is a
time and cost-effective test for many muscle disorders
with ambiguous presentation in part because of the lim-
ited capacity to screen for large and numerous genes
simultaneously. When the primary genetic modification
is unknown, immunoanalysis may be very useful to
identify primary or secondary changes that highlight
direct or functional protein interactions and guide the
search for candidate genes. As molecular technologies
are rapidly evolving, it is likely that in the near future
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available. These advances will transform the diagnostic
p a t h w a yf o rM D sa n dt h ed i a g n o s t i cr o l eo fm u s c l e
biopsy may become less central. However, despite the
availability of high throughput genetic tests, studies of
protein expression in muscle biopsies will still be neces-
sary for the diagnosis of MD. In fact, the effect of novel
mutations is not always predictable and disruption or
preservation of protein synthesis needs to be confirmed
in the muscle. In addition protein analysis has important
prognostic value, as seen for example in dystrophinopa-
thies, where the residual amount of dystrophin corre-
lates better with the phenotype than the genetic
prediction [136]. Furthermore, tests on muscle biopsy
remain crucial for evaluating the success of applied
research and clinical trials such as gene therapies that
aim to restore the missing protein.
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